

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10612179	
	Filing Date		2003-07-02	
	First Named Inventor	ROLAND KREUTZER		
	Art Unit	1635		
	Examiner Name	TRACY ANN VIVLEMORE		
Attorney Docket Number		A2038-706120		

U.S. PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S. PATENT APPLICATION PUBLICATIONS						Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS							Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button.

Add

NON-PATENT LITERATURE DOCUMENTS			Remove
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10612179
Filing Date	2003-07-02
First Named Inventor	ROLAND KREUTZER
Art Unit	1635
Examiner Name	TRACY ANN VIVEMORE
Attorney Docket Number	A2038-706120

1	SCHEFFER ET AL., "The drug resistance-related protein LRP is the human major vault protein" Nat. Med. 1:578-582 (1995).	<input type="checkbox"/>
2	SCHERR ET AL., "Quantitative Determination of Lentiviral Vector Particle Numbers by Real-time PCR" BioTechniques 31:520-526 (2001).	<input type="checkbox"/>
3	SCHLINGENSIEPEN ET AL., Blackwell Science Ltd., Vol. 6, 1997, "Antisense - From Technology to Therapy".	<input type="checkbox"/>
4	SECRIST ET AL., Abstract 21, Program & Abstracts, Tenth International Roundtable, Nucleotides, Nucleotides and their Biological Applications, Park City, Utah, Sep, 16-20 (1992).	<input type="checkbox"/>
5	SHANNON ET AL., "Modeling myeloid leukemia tumors suppressor gene inactivation in the mouse" Semin. Cancer Biol. 11:191-199 (2001).	<input type="checkbox"/>
6	SHEA ET AL., "Synthesis, hybridization properties and antiviral activity of lipid-oligodeoxynucleotide conjugates" Nucl. Acids Res. 18:3777-3783 (1990).	<input type="checkbox"/>
7	SKORSKI ET AL., "Suppression of Philadelphia Leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide" Proc. Natl. Acad. Sci. USA 91:4504-4508 (1994).	<input type="checkbox"/>
8	STETLER-STEVENSON ET AL., "Tumor Cell Interactions with the Extracellular Matrix During Invasion and Metastasis" Annu. Rev. Cell Biol. 9:541-573 (1993).	<input type="checkbox"/>
9	STRASSER ET AL., "Apoptosis Signaling" Annu. Rev. Biochem. 69:217-245 (2000).	<input type="checkbox"/>
10	SVINARCHUK ET AL., "Inhibition of HIV proliferation in MT-4 cells by antisense oligonucleotide conjugated to lipophilic groups" Biochimie 75:49-54 (1993).	<input type="checkbox"/>
11	THOMSON ET AL., "Synthesis and Properties of Diuridine Phosphate Analogues Containing Thio and Amino Modifications" J. Org. Chem. 61:6273-6281 (1996).	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10612179
Filing Date	2003-07-02
First Named Inventor	ROLAND KREUTZER
Art Unit	1635
Examiner Name	TRACY ANN VIVEMORE
Attorney Docket Number	A2038-706120

12	MARTINEZ ET AL., "Single stranded antisense siRNAs guide target RNA cleavage in RNAi," Cell, 110:563-574 (2002).	<input type="checkbox"/>
13	VAN BEUSECHEM ET AL., "Long-term expression of human adenosine deaminase in rhesus monkeys transplanted with retronvirus-infected bone-marrow cells" Proc. Natl. Acad. Sci. USA 89:7640-7644 (1992).	<input type="checkbox"/>
14	VAN ETEN, "Pathogenesis and treatment of Ph+ leukemia: recent insights from mouse models" Curr. Opin. Hematol. 8:224-230 (2001).	<input type="checkbox"/>
15	VICKERS ET AL., "Efficient Reduction of Target RNAs by Small Interfering RNA and RNase H-dependent Antisense Agents. A COMPARATIVE ANALYSIS" J. Biol. Chem. 278: 7108-7118 (2003).	<input type="checkbox"/>
16	WACHECK ET AL., "Small Interfering RNA Targeting Bcl-2 Sensitizers Malignant Melanoma" Oligonucleotides, Vol. 13 (5):393-400 (2003).	<input type="checkbox"/>
17	WAGNER, "The state of the art in antisense research" Nat. Med. 1:1116-1118 (1995).	<input type="checkbox"/>
18	WILLIAMS ET AL., "Thermodynamic Comparison of the Salt Dependence of Natural RNA Hairpins and RNA Hairpins with Non-Nucleotide Spacers" Biochemistry 35:14665-14670 (1996).	<input type="checkbox"/>
19	WILSON ET AL., "Retrovirus-mediated transduction of adult hepatocytes" Proc. Natl. Acad. Sci. USA 85:3014-3018 (1988).	<input type="checkbox"/>
20	WINK, Molekulare Biotechnologie, Wiley-VCH, 2004, 557-577.	<input type="checkbox"/>
21	WONG ET AL., "Modeling Philadelphia chromosome positive leukemias" Oncogene 20:5644-5659 (2001).	<input type="checkbox"/>
22	YOKOTA, "Tumor progression and metastasis" Carcinogenesis 21:497-503 (2000).	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10612179
Filing Date	2003-07-02
First Named Inventor	ROLAND KREUTZER
Art Unit	1635
Examiner Name	TRACY ANN VIVLEMORE
Attorney Docket Number	A2038-706120

23	ZAMORE ET AL., "Evidence that siRNAs function as guides not primers in the drosophila and human RNAi pathways," Mol. Cell, 10:537-48 (2002).	<input type="checkbox"/>
24	ZENG ET AL., "The Fetal Origin of B-Precursor Leukemia in the Eu-ret Mouse" Blood 92:3529-3536 (1998).	<input type="checkbox"/>
25	AGRAWAL ET AL., "Antisense therapeutics: is it as simple as complementary base recognition," Molecular Medicine, 6:72-81 (2000).	<input type="checkbox"/>
26	ALFONZO ET AL., "The mechanism of U insertion/deletion RNA editing in kinetoplastid mitochondria," Nucleic Acid Research, 25:3751-3759 (1997).	<input type="checkbox"/>
27	ANDERSON, "Human Gene Therapy," Nature, 392:25-30 (1998).	<input type="checkbox"/>
28	BRANCH, "A good antisense molecule is hard to find," TIBS, 23:45-50 (1998).	<input type="checkbox"/>
29	DOLINNAYA, N.G. ET AL., "Oligonucleotide circularization by template-directed chemical ligation," Nucleic Acids Research, 21:5403-5407 (1993).	<input type="checkbox"/>
30	EXPERT-BEZANCON, A. ET AL., "Precise localization of several covalent RNA-RNA cross-link in Escherichia coli 16S RNA," European Journal of Biochemistry, 136:267-274 (1983).	<input type="checkbox"/>
31	FIRE, A. ET AL., "Specific interference by ingested dsRNA," Nature, 395:854 (1998).	<input type="checkbox"/>
32	GAO H., ET AL., "Circularization of oligonucleotides by disulfide bridge formation," Nucleic Acids Research, 23:2025-2029 (1995).	<input type="checkbox"/>
33	JASCHKE, ET AL., "Synthesis and analytical characterization of RNA polyethylene glycol conjugates," Nucleosides & Nucleotides, 15:1519-1529 (1996).	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10612179
Filing Date	2003-07-02
First Named Inventor	ROLAND KREUTZER
Art Unit	1635
Examiner Name	TRACY ANN VIVEMORE
Attorney Docket Number	A2038-706120

34	KAUFMAN, R.J., ET AL., "Double-stranded RNA-activated protein kinase mediates virus -induced apoptosis: A new role for an old actor," PNAS USA, 96:11693-11695 (1999).	<input type="checkbox"/>
35	LIPSON, S.E., ET AL., "Psoralen cross-linking of ribosomal RNA," Methods in Enzymology, 164:330-341 (1988).	<input type="checkbox"/>
36	LIU, Z. R., ET AL., "Detection of a novel ATP-dependent cross-linked protein at the 5' splice site-U1 small nuclear RNA duplex by methylene blue-mediated photo-cross-linking, Molecular Cell Biology, 18:6910-6920 (1998).	<input type="checkbox"/>
37	MICURA, R. "Cyclic oligonucleotides (RNA) by solid-phase synthesis," Chem. Eur. J., 5:2077-2082 (1999).	<input type="checkbox"/>
38	RAVINDERJIT ET AL., "Regiospecific Solid-Phase Synthesis of Branched Oligonucleotides. Effect of Vicinal 2',5'- (or 2',3'-) and 3',5'-Phosphodiester Linkages on the Formation of Hairpin DNA," Bioconjugate Chemistry, 8:370-377 (1997).	<input type="checkbox"/>
39	ROSALIND, C. L., ET AL., "The C. elegans Hereditary Gene lin-4 encodes small RNAs with antisense complementary to lin-14," Cell, 75:843-854 (1993).	<input type="checkbox"/>
40	SEYDOUX, G., ET AL., "Repression of gene expression in the embryonic germ lineage of C. elegans," Nature 382:713-716 (1996).	<input type="checkbox"/>
41	THOMPSON, J. D., "Shortcuts from gene sequence to function," Nature Biotechnology, 17:1158-1159 (1999).	<input type="checkbox"/>
42	VERMA, ET AL., "Gene therapy - promises, problems, and prospects," Nature, 389:239-242 (1997).	<input type="checkbox"/>
43	WAGNER, ET AL., "Double-stranded RNA poses puzzle," Nature, 391:744-745 (1998).	<input type="checkbox"/>
44	WANG, S., ET AL., "Circular RNA oligonucleotides. Synthesis, nucleic acid binding properties, and a comparison with circular DNAs," Nucleic Acids Research, 22:2326-2333 (1994).	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10612179
Filing Date	2003-07-02
First Named Inventor	ROLAND KREUTZER
Art Unit	1635
Examiner Name	TRACY ANN VIVEMORE
Attorney Docket Number	A2038-706120

45	WANG, Z. ET AL., "RNA conformation in the Tat-TAR complex determined by site-specific photo-cross-linking," Biochem., 35:6491-6499 (1996).	<input type="checkbox"/>
46	WATKINS, K. P., ET AL., "In vivo UV cross-linking of U snRNAs that participate in trypanosome trans-splicing," Genes & Development, 5:1859-1869 (1991).	<input type="checkbox"/>
47	WENGEL, J., "Synthesis of 3'-C- and 4'-C-branched oligodeoxynucleotides and the development of locked nucleic acid (LNA)," Acc. Chem. Res., 32:301-310 (1999).	<input type="checkbox"/>
48	ZWIEB, C. ET AL., "Evidence for RNA-RNA cross-linked formation in Escherichia coli ribosomes," Nucleic Acids Research, 5:2705-2720 (1978).	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button [Add](#)

EXAMINER SIGNATURE

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.